TAP is Seventh Sense Biosystem’s proprietary blood collection platform that enables blood to be drawn through a virtually painless, one-step process.
The U.S. FDA cleared Seventh Sense Biosystem’s TAP phlebotomy device for use in hemoglobin A1c (HbA1c) testing, a standard parameter for diabetes management, this past Thursday February 23, 2017.
There is no real need for an expert. The device is placed on the upper arm. With a push of a button, an array of tiny microneedles pierces the skin. A vacuum chamber within the device then painlessly draws the blood from the pierced capillaries, where it is mixed with an anticoagulant. Two or three minutes later, TAP switches off, the patient gets on with their day and the device is sent to the laboratory for testing.
Complete story courtesy of MedCityNews